[Email id of designated official for the purpose of grievance redressal]
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2006 |
|||||
---|---|---|---|---|---|
(Rs. in Lacs) |
|||||
PARTICULARS |
Unaudited quarter 30.09.2006 |
Unaudited quarter 30.09.2005 |
Unaudited Half Year 30.09.2006 |
Unaudited Half Year 30.09.2005 |
Audited Year End 31.03.2006 |
SALES | 9100.61 |
7675.05 |
17443.07 |
14728.21 |
27437.56 |
Others Income | 12.11 |
16.82 |
23.71 |
27.56 |
182.73 |
TOTAL INCOME | 9112.72 |
7691.87 |
17466.78 |
14755.77 |
27620.29 |
Total Expenditure | 7912.94 |
6789.33 |
15237.42 |
13065.43 |
24186.29 |
Decrease in Stock in trade | -163.73 |
-556.43 |
-394.70 |
-275.30 |
-516.59 |
Consumption of raw material | 6902.06 |
6278.56 |
12464.20 |
11342.52 |
20760.28 |
Cost of Sales | 6738.33 |
5722.13 |
12858.90 |
11067.22 |
20243.69 |
Staff Cost | 302.30 |
228.56 |
592.17 |
454.73 |
1107.36 |
Other expenses | 872.31 |
838.64 |
1786.35 |
1543.48 |
2835.24 |
Interest | 383.33 |
219.89 |
713.43 |
418.51 |
1093.84 |
Depreciation | 69.20 |
33.99 |
137.35 |
66.70 |
146.48 |
PROFIT BEFORE TAX | 747.25 |
648.66 |
1378.58 |
1205.13 |
2193.68 |
Provision for Tax(Incl. FBT.) | 91.68 |
48.65 |
170.36 |
90.38 |
214.78 |
Provision for Deferred Tax | 66.15 |
28.39 |
118.30 |
30.89 |
252.29 |
Net Profit | 589.42 |
571.62 |
1089.92 |
1083.86 |
1726.61 |
Share Capital | 743.57 |
743.57 |
743.57 |
743.57 |
743.57 |
Reserves excluding | 11934 |
||||
Revaluation Reserves EPS(Basic & Diluted) | 1.59 |
1.54 |
2.93 |
2.92 |
4.64 |
AGGREGATE OF NON-PROMOTERS SHAREHOLDING | |||||
NUMBER OF SHARES | 24056475 | 24056475 | 24056475 | 24056475 | 24056475 |
% OF SHARE HOLDING | 64.70% |
64.70% |
64.70% |
64.70% |
64.70% |
Notes:- |
|||||
1. During the quarter under review, the turnover of the company grew by 18.57% and profit before Tax grew by 15.17% compared to same period during previous year. 4. The Company's new 100% Export Oriented Facility at Derabassi,Punjab,confirms to stringent TGA-Australia,MHRA-UK, MCC-South Africa & ANVISA-Brazil requirements and the unit is ready for an audit and accredition by these bodies including WHO-Geneva. 5. During the Quarter, the company has introduced 18 new products in the market. 6.The above results were reviewed by the audit committee and taken on record by Board of Directors of the company by their respective meetings held on 28th October 2006. 7 The company had recieved 04 investors complaints during the quarter under review and all of these were redressed and disposed off .Their were no pending complaints either at the beginning or end of the quarter. 8.The Company is exclusively in the Pharmaceutical business segment. 9. Previous Year Figures have been re-grouped and/or re-arranged wherever considered necessary. |
|||||
For and on Behalf of the Board of Directors |
|||||
Dated: 28.10.2006 | (Dr. Gopal Munjal) |
||||
Place: Chandigarh | Chairman |
||||